CD4 and inflammatory bowel disease: Given that ILCs are CD4-negative cells and the expression of α4β7 integrin on ILCs in the mucosa of patients with inflammatory bowel disease is low25, ILCs may play a central role in the pathogenesis of UC in patients who show a poor response to vedolizumab.